Twist Bioscience Corp
For the period ended Sep 30, 2024. Filed Nov 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 18, 2024
TWST$135.34+12.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common stock · Additional paid-in capital · Accumulated other comprehensive income / (loss) · Accumulated deficit · Total stockholders' equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||||
| Balances as of September 30, 2021 | 49,499 | $— | $1,190,828 | $546 | $(610,553) | $580,821 | |||||
| Issuance of common stock in public offerings, net of underwriting discounts, commissions and offering expenses of $17,678 | 5,227 | — | 269,822 | — | — | 269,822 | |||||
| Vesting of restricted stock units | 365 | — | — | — | — | — | |||||
| Issuance of shares under the employee stock purchase plan | 97 | — | 4,010 | — | — | 4,010 | |||||
| Exercise of stock options | 486 | — | 5,952 | — | — | 5,952 | |||||
| Repurchase of early exercised stock options | — | — | — | — | — | — | |||||
| Business acquisition | 988 | — | 77,122 | — | — | 77,122 | |||||
| Stock-based compensation | — | — | 79,664 | — | — | 79,664 | |||||
| Net exercise of stock warrants | — | — | — | — | — | — | |||||
| Other comprehensive income | — | — | — | (2,389) | — | (2,389) | |||||
| Repurchase of common stock for income tax withholdings | (139) | — | (7,754) | — | — | (7,754) | |||||
| Net loss | — | — | — | — | (217,863) | (217,863) | |||||
| Balances as of September 30, 2022 | 56,523 | — | 1,619,644 | (1,843) | (828,416) | 789,385 | |||||
| Vesting of restricted stock units | 648 | — | — | — | — | — | |||||
| Issuance of shares under the employee stock purchase plan | 217 | — | 3,937 | — | — | 3,937 | |||||
| Exercise of stock options | 118 | — | 1,379 | — | — | 1,379 | |||||
| Business acquisition | 277 | — | 5,860 | — | — | 5,860 | |||||
| Stock-based compensation | — | — | 30,821 | — | — | 30,821 | |||||
| Other comprehensive loss | — | — | — | 1,087 | — | 1,087 | |||||
| Repurchase of common stock for income tax withholdings | (226) | — | (4,419) | — | — | (4,419) | |||||
| Net loss | — | — | — | — | (204,618) | (204,618) | |||||
| Balances as of September 30, 2023 | 57,557 | — | 1,657,222 | (756) | (1,033,034) | 623,432 | |||||
| Impact of ASU 2016-13 adoption (Note 2) | — | — | — | — | (148) | (148) | |||||
| Vesting of restricted stock units | 896 | — | — | — | — | — | |||||
| Issuance of shares under the employee stock purchase plan | 177 | — | 3,765 | — | — | 3,765 | |||||
| Exercise of stock options | 384 | — | 7,100 | — | — | 7,100 | |||||
| Stock-based compensation | — | — | 51,007 | — | — | 51,007 | |||||
| Other comprehensive loss | — | — | — | 234 | — | 234 | |||||
| Repurchase of common stock for income tax withholdings | (137) | — | (3,975) | — | — | (3,975) | |||||
| Net loss | — | — | — | — | (208,726) | (208,726) | |||||
| Balances as of September 30, 2024 | 58,877 | $— | $1,715,119 | $(522) | $(1,241,908) | $472,689 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.